Heidi Health

What is Heidi Health and who sells it?

Heidi's home page describes "clinical-grade AI for physicians and health systems, built on one of the world's most used ambient scribes". It lists four verbs: it listens to "every word of the visit", writes "your note, then every document after it", answers with "clinical evidence, cited from the full paper", and "works through the admin the visit leaves". The evidence layer is grounded in literature from Wiley, Cochrane, BMJ Group and NEJM (Heidi website, read October 2026).

The company is Heidi Health, based in Melbourne, Australia. Dr Thomas Kelly is CEO, and co-founders include Waleed Mussa and Yu Liu. The founding year depends on the source: one gives 2021 (as Oscer), Tracxn gives 2019, and another gives 2020, so we leave it as "around 2020".

Funding is reported by the press. Business News Australia reported a US$65M Series B in October 2025 led by Point72 at a US$465M valuation. DealStreetAsia reported a US$100M Series C in September 2026 led by Blackbird at about US$900M, plus US$240M of customer-acquisition finance from General Catalyst. Forbes Australia reports an A$1.26B valuation, which does not match the US figures. No ownership changes are reported.

What does Heidi do well?

The product reaches past the note. Besides ambient capture and templates, the home page lists documents produced after the visit, such as referrals, letters and care plans. It also lists morning prep, a follow-up digest, a patient recap that the clinician approves before sending, preparation for multidisciplinary team meetings, and shift handover. Role tabs address doctors, nurses, allied health and practice managers.

"Note insights" suggest entries for a personal word library and automatic edit rules based on what the clinician changes. How well that works is unknown, since no outcome data exists.

Epic is supported. Heidi publishes an Epic integration page describing SMART on FHIR with Haiku and Hyperdrive, and the product is listed in the Epic Showroom.

Access is the other strength. Heidi's pricing page shows a free seat with a weekly allowance, a Clinician plan with a 14-day trial, and Teams or Enterprise plans on request. One poster on r/FamilyMedicine (October 2025) said they had "previously" been using the free version of Heidi while choosing among three paid scribes, so the free tier does get used as an entry point.

The Trust Center lists SOC 2 with a Type II report renewed annually, ISO 27001:2022, ISO/IEC 42001:2023 for AI management, HIPAA, GDPR, UK Cyber Essentials Plus, C5, TX-RAMP, PIPEDA and the Australian Privacy Principles, with reports available by email on request. Heidi says it does not train models on consultation data and signs Business Associate Agreements with vendors. HITRUST is not stated, and neither is FDA or Australian TGA status on the pages read.

Where does Heidi fall short?

Proof is the main gap. Heidi's own "Pressure Points" research and a 2025 KLAS spotlight are known only from secondary sources.

Complaints exist, though they come from competitors. Reviews by Twofold, Vero Scribe and Commure, all of which sell scribes, report fabricated details such as smoking status (a 2.0-star review in October 2025) and dropped recordings. Weigh them with the bias their authors carry. Heidi's own usage policy states that output "may not be free from errors" and that users must review it, which applies to every ambient scribe.

Cost draws comments. In a February 2026 r/healthIT thread on the best AI scribe, a poster wrote of Heidi "several ppl said it's expensive". The vendor page shows no amounts, so any figure is an outside estimate, covered in the pricing section.

How does Heidi compare with Abridge, DAX Copilot and Freed?

Heidi's competitors include Abridge, DAX Copilot, Nabla, Freed, Suki, Tali, Commure, Mentalyc and Vero Scribe, and web roundups most often set Heidi against Abridge, Nabla, Freed and Suki.

Against Abridge and DAX Copilot, the difference is buyer and evidence. Both are enterprise products sold by quote, with multi-site studies behind them. Heidi is a product you can sign up for yourself, and no such study was found for it. A health system that wants published Epic deployments at scale should start with those two, and an individual who wants a scribe by Friday can sign up to Heidi directly.

Against Freed, the contest is about price transparency. Freed publishes dollar amounts on its pricing page: $59 and $39 a month for a capped Starter plan and $119 or $104 for Premier. Heidi publishes tiers without amounts. A clinician who wants to compare costs before signing up has more to work with at Freed. Choose Heidi if the extras (letters, evidence answers, handover) matter, and Freed if the monthly cost and a capped, predictable plan matter more.

What does the evidence say about Heidi?

Very little. No peer-reviewed study of Heidi and no scribe-specific trial for Heidi is published, and no community thread is about it. The vendor's own research and a KLAS spotlight are known only from secondary sources, which say they reported reduced documentation time.

The multi-vendor and randomised studies of ambient scribes did not include Heidi, so none of their results transfer to it, and a pilot with your own visits is the only direct test.

What does Heidi cost?

As of October 2026 Heidi's own pricing page shows no dollar amounts: a free seat with a weekly allowance, a Clinician plan with a 14-day trial, and custom Teams or Enterprise plans. Third parties estimate the Clinician plan at about $150 per user per month, with another source reporting $110 a month billed yearly. Those sources sell competing scribes and disagree on whether the figure is monthly or annual, so it is an estimate.

Who is Heidi for?

A solo GP or specialist who wants to trial a scribe without procurement can start on the free seat and move to the Clinician plan if it fits. A multidisciplinary clinic with nurses and allied health, wanting letters, recaps and handover from one tool, is the second fit, and a UK or Australian practice that needs GDPR, Australian privacy or Cyber Essentials Plus coverage listed on a trust page is the third.

It is a poor fit for a US health system that needs independent outcome data and a mature Epic rollout, and for a clinician who needs EHR write-back on the lowest tier, since competitor reviews say write-back is limited to a higher one.

The verdict

Heidi is worth a trial and not yet an institutional bet. The free seat lowers the cost of finding out, the trust page is detailed, and the product does more than notes. The evidence base is missing, the complaints found come from competitors, and the price is not published. In a two-week Clinician trial, record how long you spend editing each note and compare it with your current minutes.